Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

OBJECTIVE: The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown whether patients who fail to respond to the first onabotulinumtoxinA treatment cycle will respond to subsequent treatment c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurol Neurosurg Psychiatry
Main Authors: Silberstein, Stephen D, Dodick, David W, Aurora, Sheena K, Diener, Hans-Christoph, DeGryse, Ronald E, Lipton, Richard B, Turkel, Catherine C
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Migraine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552933/
https://ncbi.nlm.nih.gov/pubmed/25500317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2013-307149
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados